BioCardia Inc. Common Stock (BCDA)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, have durable advantages, and sell at a margin of safety. BioCardia does not yet fit that mold. It is a clinical-stage regenerative medicine company with 17 employees, and its lead candidate CardiAMP is in Phase III for ischemic heart failure and refractory angina. The commercial record is practically nonexistent: in fiscal 2023, the year ended 2023-12-31, revenue was $477,000; in fiscal 2024, the year ended 2024-12-31, revenue was $58,000; and in fiscal 2025, the year ended 2025-12-31, revenue was not available. Meanwhile, net losses were $11.6 million in fiscal 2023, $7.9 million in fiscal 2024, and $8.2 million in fiscal 2025. More recent filings show net losses of $2.3 million in fiscal Q1 2026, the quarter ended 2026-03-31, and $1.6 million in fiscal Q2 2026, the quarter ended 2026-06-30, so the burn continues.

In plain English: BioCardia is a small clinical-stage biotechnology company trying to develop cell therapies for heart and lung diseases. The business looks weak: it has no meaningful revenue, loses money every year, and burns cash. At about $0.99 per share with a $15.0 million market value, the price looks expensive relative to its tiny sales and continuing losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer